The Supreme Court Ruling in Sandoz v Amgen: A Victory for Follow-on Biologics
- PMID: 29131908
- DOI: 10.1001/jamainternmed.2017.6145
The Supreme Court Ruling in Sandoz v Amgen: A Victory for Follow-on Biologics
Erratum in
-
Imprecise Percentages.JAMA Intern Med. 2018 Jan 1;178(1):157. doi: 10.1001/jamainternmed.2017.7836. JAMA Intern Med. 2018. PMID: 29336536 No abstract available.
Similar articles
-
Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.Cornell Law Rev. 2008 Jul;93(5):939-80. Cornell Law Rev. 2008. PMID: 18618965 No abstract available.
-
The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly.Cornell Law Rev. 2008 Jul;93(5):981-1002. Cornell Law Rev. 2008. PMID: 18618967 No abstract available.
-
Aftermath of the Supreme Court ruling on health reform.J Allied Health. 2012 Fall;41(3):99-105. J Allied Health. 2012. PMID: 22968770 No abstract available.
-
From arguments to Supreme Court opinions in Planned Parenthood v. Casey.PS (Wash DC). 1993 Mar;26(1):53-8. PS (Wash DC). 1993. PMID: 12085874 Review. No abstract available.
-
Biosimilars in the United States: Emerging Issues in Litigation.BioDrugs. 2017 Jun;31(3):189-205. doi: 10.1007/s40259-017-0216-7. BioDrugs. 2017. PMID: 28424972 Review.
Cited by
-
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.Oncologist. 2019 Apr;24(4):537-548. doi: 10.1634/theoncologist.2018-0341. Epub 2019 Mar 6. Oncologist. 2019. PMID: 30842244 Free PMC article.
-
The FDA's New Guideline "Generally Accepted Scientific Knowledge" (GASK): An Opportunity to Expedite the Approval of Biosimilars.Pharmaceuticals (Basel). 2023 Oct 25;16(11):1517. doi: 10.3390/ph16111517. Pharmaceuticals (Basel). 2023. PMID: 38004383 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
